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Aim: To determine whether the total anti-delta antibody enzyme immunoassay (EIA) test results can be used to predict viremia.
Materials and methods: The EIA index value of an anti-delta total antibody assay was determined in 76 serum samples obtained from 67
patients positive for the anti-hepatitis delta virus (HDV) antibody. The presence of HDV RNA was investigated by reverse transcriptase
polymerase chain reaction (RT-PCR). The relation between the RT-PCR result and EIA index was evaluated by ROC analysis.
Results: Of the 76 total samples, 56 (74%) anti-HDV–positive samples were found to be PCR-positive. The samples with EIA index
values below 75.75 were PCR-negative, while samples with index values above 102.55 were PCR-positive. When HDV RNA presence is
considered as the gold standard, the sensitivity, specificity, and positive and negative predictive values of the chosen EIA index (100.10)
in predicting viremia were 93%, 80%, 93%, and 76%, respectively.
Conclusion: HDV RNA is the most reliable marker for the diagnosis of active HDV infection, and EIA index value is closely related to
viral RNA presence.
Key words: Anti-HDV enzyme immunoassay, ROC analysis, HDV RNA, reverse transcriptase polymerase chain reaction

1. Introduction
Hepatitis delta virus (HDV) infection is an important
health problem causing fulminant hepatitis, chronic liver
disease, cirrhosis, and hepatocellular cancer. HDV is an
enveloped, negative-sense, single-stranded RNA virus. It
is a satellite of the hepatitis B virus (HBV) and requires
a surface antigen of hepatitis B virus (HBsAg) for its
assembly and transmission (1,2). Simultaneous infection
with HDV and HBV results in coinfection in an HBVnaïve individual, whereas HDV infection in a patient
who is already chronically infected with HBV causes
superinfection. HDV superinfection frequently leads to
chronic hepatitis D, while a minority of coinfected cases
may progress to chronicity (1,3).
It is estimated that approximately 5% of global HBsAg
carriers (approximately 15 million people) are infected
with HDV (1). Although HDV infection is distributed
worldwide, its prevalence shows geographic differences.
It is endemic in the Mediterranean countries, including
Turkey. While anti-HDV seroprevalence showed a
significant reduction in Turkey since the 1980s, the studies
done in the 2000s give a mean rate of 2.9% for asymptomatic
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HBsAg carriers, 11% for chronic hepatitis B, and 24% for
liver cirrhosis patients (4). Presence of anti-HDV may
rise up to 45.5% among chronic HBV patients in eastern
regions of Turkey (5). Although overall HDV incidence in
West Europe might be decreasing, studies done in some
countries show that HDV is not a vanishing disease due to
migration from regions with a higher prevalence such as
East Europe or Africa (6). Nucleotide sequence analysis of
several isolates allowed classification of HDV into at least 8
genotypes, which also shows a geographic distribution (7).
Genotype 1 is dominant in Turkey (8,9).
The diagnosis of HDV infection is made by detecting
anti-HDV antibodies and/or viral components, i.e. HDV
RNA or HDVAg. Serum HDVAg detection does not
provide high diagnostic sensitivity since the amount of
detectable viral antigen varies according to the stage of
infection and to the titer of circulating antibodies that
may sequester the antigen. There is also broad sensitivity
variability among the commercial HDVAg assays
(10). Total anti-HDV antibody detection by enzyme
immunoassay (EIA) is generally the preferred method
for the initial screening for HDV infection among HBV-
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infected patients (6). If the patient is anti-HDV positive,
the ongoing replication is evaluated by the presence of
serum HDV RNA, since only a part of the seropositive
patients are viremic and viremia indicates potential for
liver damage (11–13). Reverse transcriptase polymerase
chain reaction (RT-PCR) is the most frequently selected
method for viral RNA detection due to its high sensitivity
(14). However, HDV RNA detection assays are mostly
homemade assays that lack standardization and are laborintensive and costly compared to EIAs (15,16). Although
screening anti-HDV EIAs gives a qualitative result,
further information can be gained from the strength of
the reaction signal. In the present study, the relationship
between anti-HDV EIA index value and HDV RT-PCR is
examined in order to determine whether EIA results can
be used to predict viremia.
2. Materials and methods
2.1. Patients
A total of 76 serum samples from 67 patients with a positive
total anti-HDV antibody test result were evaluated. The
anti-HCV and anti-HIV antibodies were negative while
HBsAg and total anti-HBc antibody were positive in all
of the patients. The serum samples were collected from
patients who were being followed by 2 different medical
centers (30 patients from the hospital of the İstanbul
University School of Medicine and 37 patients from the
hospital of Dokuz Eylül University). They were aliquoted
and stored at –70 °C.
2.2. Detecting anti-HDV antibody by EIA
Anti-HDV antibody status of the sera was tested by a
commercial anti-delta total antibody EIA kit (Hepanostika
HDV, Organon Teknika, the Netherlands; the assay is
currently not commercially available). The assay and
calculation of the EIA index with absorbance values
were performed with the TekTime instrument according
to the manufacturer’s instructions. EIA index value was
automatically determined by dividing (the mean of the
negative control’s absorbance – sample absorbance) by
(the mean of the negative control’s absorbance – mean of
the positive control’s absorbance) and then multiplying by
100.
2.3. HDV RNA RT-PCR
The presence of HDV RNA in serum samples was studied
by RT-PCR using a set of primers targeting the delta antigen

gene (Table 1). The nucleic acid was extracted from 200 µL
of the patient’s serum using a High Pure Viral Nucleic Acid
Kit (Roche Applied Science, Germany) according to the
manufacturer’s instructions.
For cDNA synthesis, 5 µL of extracted RNA was mixed
with 50 pmol of antisense primer (P-1291). The reaction
tube was held 5 min at 65 °C and then cooled on ice. The
14-µL reaction mixture containing 5X buffer, 10 U RNase
inhibitor (Roche Applied Science), 10 U AMV reverse
transcriptase (Roche Applied Science), and 200 µM dNTP
mix (PCR Nucleotide Mix, Roche Applied Science) was
added to each reaction tube. Reverse transcription was
performed by holding the tubes at 42 °C for 60 min and
then at 72 °C for 10 min.
cDNA amplification was carried out in a 50-µL
PCR mixture containing 5 µL cDNA, 1.5 mM MgCl2,
200 µM dNTP mix, 25 pmol sense primer (P-889), 12.5
pmol antisense primer (P-1291), 2.5 µL hot start DNA
polymerase (Fast Start Taq DNA Polymerase, Fermentas,
Lithuania), and 10X buffer. The tubes were placed in a
thermal cycler (PerkinElmer GeneAmp 9600). Primary
denaturation was performed for 6 min at 95 °C, followed
by 35 cycles of 94 °C for 1 min, 55 °C for 1 min, and 72 °C
for 2 min. The final extension step was at 72 °C for 10 min.
In order to prevent contamination during PCR, all the
necessary measures were strictly taken. In each PCR run,
1 positive and 1 negative control were used along with the
patient samples. The PCR products were electrophoresed
in 2% agarose gel, stained with ethidium bromide, and
visualized under UV light. EIA and RT-PCR tests were
performed twice for each sample.
2.4. Statistical analysis
Receiver operating characteristic (ROC) analysis (SPSS
11.0) was used to examine the correlation between the RTPCR results and the EIA index.
3. Results
Fifty-six of the 76 anti-HDV–positive samples (73.6%) had
detectable HDV RNA (Figure 1). All of the samples with
an anti-HDV EIA index value below 75.75 were HDV RNA
negative, while samples with an index value above 102.55
were HDV RNA positive. The EIA index of 100.10 was
chosen as the threshold value for predicting HDV viremia
according to ROC analysis. Fifty-two of the 56 HDV RNA–
positive samples (92.8%) had an EIA index of >100.10.

Table 1. The primers used for HDV RNA RT-PCR.
Primer

Location (nt)

P-889

Sense

5’-ATGCCATGCCGACCCGAAGAGGAA-3’

889–912

P-1291

Antisense

5’-GAAGGAAGGCCCTCGAGAACAAGA-3’

1291–1268

Product length
403 bp
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PK

P-1

P-2

NK

P-3

ROC

1.0

bp

Sensitivity

0.8
2642 

0.5

500 
0.3

250 

0.0
0.0

Figure 1. HDV RNA RT-PCR products of 3 patients’ sera.
Amplicons were visualized on a 2% agarose gel stained with
ethidium bromide. M: Marker; PK: positive control; NK: negative
control; P-1: HDV RNA-negative patient; P-2 and P-3: HDV
RNA-positive patients with a specific product size of 403 bp.

Four of the 20 HDV RNA negative samples had an EIA
index of ≥100.10 while the index values of the remaining
16 samples (80%) were below this threshold. When the
presence of HDV RNA in the serum was accepted as the
gold standard, the sensitivity, specificity, and positive and
negative predictive values of the threshold EIA index (i.e.
100.10) for predicting viremia were 93%, 80%, 93%, and
76%, respectively (Table 2). ROC analysis showed that the
EIA index value of a PCR-positive sample would have a
higher result with a 93% probability than a PCR-negative
sample (ROC area = 0.934) (Figure 2).
4. Discussion
Total anti-HDV antibody detection by EIA is widely
used for the diagnosis of HDV infection. There are
several commercial anti-HDV assays. They are relatively
standardized, cost-effective, and easy to apply, and they
can be automated for assaying a large number of samples
(10). It is important to differentiate chronic HDV infection
with an ongoing viral replication from a resolved infection
in an anti-HDV–positive patient. Methods such as the
titration of total anti-HDV and/or anti-HDV IgM and
differentiation of monomeric anti-HDV IgM (7S) from

0.3

0.5
1-specificity

0.8

1.0

Figure 2. The sufficiency analysis of EIA index in predicting
viremia ( ROC area: 0.93).

the pentameric (19S) form have been used for identifying
various clinical forms of delta infection (15,17,18).
However, none of these procedures are suitable for the
routine diagnostic laboratory. In an epidemiological study
done with an in-house anti-HDV EIA, it was shown that
the optical density (OD) value was significantly higher in
the HDV RNA-positive individuals compared to HDV
RNA-negative subjects, but determination of a cutoff
value was not attempted (19). The aim of this study was to
use the EIA index of the total anti-HDV assay to predict
viremia. This can easily be calculated while performing the
screening assay.
HDV RNA is an important tool to evaluate seropositive
individuals since viremia is the best marker of viral
replication and plays a major role in the pathogenesis
of liver injury (11,17). Its detection requires a highly
sensitive nucleic acid assay such as RT-PCR. HDV RNA
was detected in 22%–80% of anti-HDV–positive patients,
depending on the study group and the nucleic acid assay
(8,19,20). The need for a specifically designed laboratory
and educated personnel, the lack of standardization, and
the use of homemade assays are the problems related to
HDV RNA detection. Persistence of high titers of antiHDV is consistent with chronic HDV infection and
presence of HDV RNA (1,10,17). However, determination
of antibody titer requires serial dilution of the serum
sample. In the present study, EIA index was used instead of

Table 2. The sensitivity, specificity, and positive and negative predictive values of 3 different EIA index values in predicting viremia.
EIA index value

Sensitivity (%)

Specificity (%)

PPV (%)

NPV (%)

75.75

100

60

88

100

100.10

93

80

93

76

102.55

36

100

100

36
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anti-HDV titer. The results confirmed that the EIA index
of the total anti-HDV assay was closely related to HDV
RNA positivity. The ROC analysis showed that, for this
EIA assay, when the threshold value of 100.10 was chosen
for the EIA index to predict viremia, the specificity and
sensitivity were 80% and 93%, respectively. Prediction of
viremia by the EIA index can minimize the amount of
nucleic acid testing needed while improving the clinical
significance of the screening assay. A similar approach
was recommended by the CDC for the diagnosis of HCV
infection (21). This guideline suggests using the sample to
cut-off OD ratio of the reactive anti-HCV test to determine
the next step in the algorithm. As seen with HCV assays,
EIA index values used for prediction of viremia depend on
the antibody and nucleic acid detection tests used due to
a lack of standardization between assays. This factor could
be more important for HDV, since international standards
for HDV RNA assays are not yet developed (22). Therefore,
the EIA index chosen for the prediction of viremia in this
study is only valid for the specified conditions.
The limitations of diagnosis by the detection of antiHDV antibodies are the potential for false negative

results in the early phase of the infection (before antibody
seroconversion) and infection in immunosuppressed
patients. HDV RNA detection has a crucial role in these
circumstances (1). Viral load assessment also helps in
monitoring the response to the therapy (23).
In conclusion, the search for a total anti-HDV antibody
is widely used as the initial screening method for the
diagnosis of HDV infection. As a second step, the presence
of HDV RNA should be determined in an anti-HDV–
positive patient, since liver injury is related to chronic
viremia. The present study showed that the EIA index
of the reactive total anti-HDV assay is highly correlated
with the presence of HDV RNA detected by RT-PCR.
It can be used as a predictor of viremia in a diagnostic
microbiology laboratory. It might be necessary for each
laboratory to determine their own EIA index due to lack
of standardization between HDV RNA detection assays.
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